• The launch follows Dr. Reddy's receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company's readiness to serve Canadian patients
• Dr. Reddy's is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
• Canada is the first G7 country to grant market authorization for generic Semaglutide Injection

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.